PapersFlow Research Brief
Blood Coagulation and Thrombosis Mechanisms
Research Guide
What is Blood Coagulation and Thrombosis Mechanisms?
Blood coagulation and thrombosis mechanisms refer to the biochemical and cellular processes that initiate blood clotting to achieve hemostasis and the pathological formation of thrombi leading to vascular occlusion, involving factors such as thrombin, protease-activated receptors, and genetic variants like Factor V Leiden.
The field encompasses 59,745 papers on thrombosis, coagulation disorders, and associations with conditions including pregnancy, inflammation, and pediatric stroke. Key topics include thrombin signaling, protease-activated receptors, thrombophilia, antithrombotic therapy, and roles of coagulation factors in pathology. Research highlights genetic mutations, such as those in factor V and prothrombin, that elevate thrombosis risk.
Topic Hierarchy
Research Sub-Topics
Thrombin Signaling Pathways
This sub-topic explores thrombin's role as a serine protease in coagulation cascade amplification and its G-protein coupled receptor signaling. Researchers investigate downstream effects on platelet activation and endothelial responses.
Protease-Activated Receptors in Thrombosis
This sub-topic focuses on PAR1, PAR4, and PAR2 activation by thrombin and other proteases in platelet aggregation and vascular inflammation. Researchers study biased agonism and receptor crosstalk in thrombotic diseases.
Inherited Thrombophilias
This sub-topic examines genetic mutations like Factor V Leiden and Prothrombin G20210A causing hypercoagulability and venous thromboembolism risk. Researchers conduct genotype-phenotype studies and population screening guidelines.
Antithrombotic Therapy
This sub-topic covers direct oral anticoagulants (DOACs), warfarin management, and reversal agents for stroke prevention and VTE treatment. Researchers perform clinical trials comparing efficacy-safety profiles across indications.
Coagulation in Pregnancy
This sub-topic investigates hypercoagulability of pregnancy, VTE risk stratification, and thrombophilia-associated complications like placental abruption. Researchers evaluate prophylaxis regimens and maternal-fetal outcomes.
Why It Matters
Understanding blood coagulation and thrombosis mechanisms guides antithrombotic therapies for venous thromboembolism (VTE) and stroke. "Antithrombotic Therapy for VTE Disease" by Kearon et al. (2012) provides evidence-based recommendations for managing VTE with anticoagulants, reducing recurrence rates. "Tissue Plasminogen Activator for Acute Ischemic Stroke" by The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) demonstrated that intravenous t-PA improves clinical outcomes in acute ischemic stroke when administered within 3 hours, despite hemorrhage risks, influencing emergency protocols worldwide. "Oral Rivaroxaban for Symptomatic Venous Thromboembolism" by Bauersachs (2010) showed rivaroxaban's efficacy as a single-drug regimen, simplifying treatment and improving patient adherence in VTE management.
Reading Guide
Where to Start
"Mutation in blood coagulation factor V associated with resistance to activated protein C" by Bertina et al. (1994) introduces the foundational genetic mechanism of thrombophilia through factor V resistance, providing clear molecular insights accessible to newcomers.
Key Papers Explained
"Mutation in blood coagulation factor V associated with resistance to activated protein C" by Bertina et al. (1994) discovered the factor V Leiden mutation impairing protein C pathway. "A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis" by Poort et al. (1996) extended this by identifying prothrombin G20210A as another thrombophilia risk factor. "Antithrombotic Therapy for VTE Disease" by Kearon et al. (2012) builds on these genetics by integrating them into clinical guidelines for therapy.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes clinical translation of genetic findings into antithrombotic strategies, as seen in trials for rivaroxaban and t-PA protocols, with focus on balancing bleeding risks in sepsis and stroke.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Tissue Plasminogen Activator for Acute Ischemic Stroke | 1995 | New England Journal of... | 11.6K | ✕ |
| 2 | Efficacy and Safety of Recombinant Human Activated Protein C f... | 2001 | New England Journal of... | 6.1K | ✓ |
| 3 | Antithrombotic Therapy for VTE Disease | 2012 | CHEST Journal | 6.1K | ✓ |
| 4 | Matrix Metalloproteinases: Regulators of the Tumor Microenviro... | 2010 | Cell | 4.9K | ✓ |
| 5 | How Matrix Metalloproteinases Regulate Cell Behavior | 2001 | Annual Review of Cell ... | 3.9K | ✓ |
| 6 | Matrix Metalloproteinases | 1999 | Journal of Biological ... | 3.9K | ✓ |
| 7 | Mutation in blood coagulation factor V associated with resista... | 1994 | Nature | 3.8K | ✕ |
| 8 | Oral Rivaroxaban for Symptomatic Venous Thromboembolism | 2010 | New England Journal of... | 3.2K | ✓ |
| 9 | A common genetic variation in the 3'-untranslated region of th... | 1996 | Blood | 3.1K | ✓ |
| 10 | Matrix metalloproteinases and the regulation of tissue remodel... | 2007 | Nature Reviews Molecul... | 2.9K | ✓ |
Frequently Asked Questions
What is the role of tissue plasminogen activator in acute ischemic stroke?
Tissue plasminogen activator (t-PA) is used as thrombolytic therapy for acute ischemic stroke. "Tissue Plasminogen Activator for Acute Ischemic Stroke" by The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) reported improved clinical outcomes with intravenous recombinant t-PA when given within 3 hours of symptom onset in a randomized trial. Early trials noted high intracerebral hemorrhage rates, leading to cautious application.
How does Factor V mutation contribute to thrombosis?
A mutation in blood coagulation factor V causes resistance to activated protein C, impairing anticoagulation. "Mutation in blood coagulation factor V associated with resistance to activated protein C" by Bertina et al. (1994) identified this variant linked to increased thrombosis risk. The mutation disrupts factor V inactivation, promoting clot formation.
What genetic variation affects prothrombin levels and venous thrombosis?
A common G20210A variation in the 3'-untranslated region of the prothrombin gene elevates plasma prothrombin levels. "A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis" by Poort et al. (1996) found this polymorphism in patients with familial venous thrombophilia. It increases venous thrombosis risk through higher prothrombin expression.
What are recommendations for antithrombotic therapy in VTE?
Antithrombotic therapy for VTE disease involves anticoagulants to prevent recurrence. "Antithrombotic Therapy for VTE Disease" by Kearon et al. (2012) outlines guidelines on duration and agents like vitamin K antagonists. Therapy balances efficacy against bleeding risks based on patient factors.
How does rivaroxaban treat venous thromboembolism?
Rivaroxaban provides a single-drug oral approach for acute and extended VTE treatment. "Oral Rivaroxaban for Symptomatic Venous Thromboembolism" by Bauersachs (2010) demonstrated its noninferiority to standard therapy in trials NCT00440193 and NCT00439725. It improves benefit-to-risk profile over multi-drug regimens.
What is the significance of activated protein C in sepsis?
Recombinant human activated protein C (drotrecogin alfa) reduces mortality in severe sepsis. "Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis" by Bernard et al. (2001) showed significant mortality reduction but increased bleeding risk. It targets coagulation dysregulation in sepsis.
Open Research Questions
- ? How do matrix metalloproteinases interact with coagulation factors to influence thrombus stability in inflammatory conditions?
- ? What are the long-term outcomes of rivaroxaban versus traditional anticoagulants in patients with prothrombin gene mutations?
- ? How does Factor V Leiden modify responses to activated protein C in pregnancy-associated thrombosis?
- ? What mechanisms link thrombin signaling via protease-activated receptors to pediatric stroke risk?
- ? How do genetic thrombophilia variants like prothrombin G20210A interact with environmental factors in VTE pathogenesis?
Recent Trends
The field maintains 59,745 works with sustained focus on genetic thrombophilia from papers like Bertina et al. and Poort et al. (1996), alongside therapy advancements in Kearon et al. (2012) and Bauersachs (2010).
1994No recent preprints or news reported in the last 6-12 months indicate steady maturation rather than rapid shifts.
Research Blood Coagulation and Thrombosis Mechanisms with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Blood Coagulation and Thrombosis Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers